In the latest trading session, Organon (OGN) closed at $18.10, marking a +0.56% move from the previous day. This move lagged the S&P 500's daily gain of 0.77%. Elsewhere, the Dow saw an upswing of 0.47%, while the tech-heavy Nasdaq appreciated by 0.87%. The pharmaceutical company's stock has dropped by 12.07% in the past month, falling short of the Medical sector's loss of 3% and the S&P 500's gain of 4.87%. The upcoming earnings release of Organon will be of great interest to investors. The company's earni ...

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is o ...

In the latest market close, Organon (OGN) reached $18.58, with a -1.33% movement compared to the previous day. This change lagged the S&P 500's 0.01% gain on the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. Prior to today's trading, shares of the pharmaceutical company had lost 14.72% over the past month. This has lagged the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21% in that time. Analysts and investors alike will be keeping a close ey ...

In the latest market close, Organon (OGN) reached $19.17, with a +0.74% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.4% for the day. On the other hand, the Dow registered a gain of 0.62%, and the technology-centric Nasdaq increased by 0.6%. The pharmaceutical company's stock has dropped by 15.31% in the past month, falling short of the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%. The investment community will be closely monitoring the ...

Organon (OGN) ended the recent trading session at $20.47, demonstrating a +0.89% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.54%. On the other hand, the Dow registered a gain of 0.72%, and the technology-centric Nasdaq increased by 0.65%. Shares of the pharmaceutical company witnessed a gain of 0.35% over the previous month, trailing the performance of the Medical sector with its gain of 4.37% and the S&P 500's gain of 4.86%. The upcoming earn ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this pharmaceutical company have returned +1%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 1.2%. The key question now is: What could be the stock's future direction? Altho ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this pharmaceutical company have returned +0.6% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 2.5% over this period. Now the key question is: Where could the stock be headed in the near term? Alt ...

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this pharmaceutical company have returned -2.5% over the past month versus the Zacks S&P 500 composite's -3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 0.7% over this period. Now the key question is: Where could the stock be headed in the near term? Although media re ...

销售情况 - 2024年上半年公司全球销售额为32.29亿美元，同比增长3%[140] - 美国市场销售额为7.58亿美元，同比增长9%[136] - 国际市场销售额为24.71亿美元，同比增长1%[136] - Nexplanon单支植入式避孕套在美国和国际市场销售均有增长，分别为13%和22%[148][141] - NuvaRing阴道避孕环在美国市场销售下降36%，主要受到仿制药竞争和政府折扣率上升的影响[149] - 生物类似药Hadlima在2023年7月在美国上市后销售大幅增长273%[153] - 生物类似药Ontruzant在巴西政府招标采购中需求增加，但在美国受到不利折扣率影响和欧洲需求下降[141] - 部分成熟品牌如Zetia/Vytorin和Cozaar/Hyzaar在日本和中国市场受到竞争和政策影响销售下降[139][142] 生物类似药销售情况 - 雷米卡德生物类似药Renflexis销售下降2%,主要由于美国折扣率上升,但加拿大需求增长抵消了部分影响[155] - 赫赛汀生物类似药Ontruzant销售增长46%和62%,主要由于巴西政府招标带来的需求增加,但美国不利折扣率和欧洲需求下降抵消了部分增长[156] - 恩布瑞生物类似药Brenzys销售保持相对稳定,六个月销售增长13%主要由于巴西政府订单时间性影响[157] - 修美乐生物类似药Hadlima在美国2023年7月上市后,三个月和六个月销售分别为2800万美元和5800万美元,同时国际市场也有适度增长[158] 成熟品牌销售情况 - 主要成熟品牌中,降胆固醇药物Zetia/Vytorin和Atozet销售下降,主要受日本需求下降、竞争影响和ERP系统实施影响[162,163] - 降压药Cozaar/Hyzaar销售下降,主要受中国VBP政策影响[164] - 哮喘药物Singulair销售增长16%,主要由于中国需求增加,但六个月销售下降5%受日本需求和价格下降影响[167] - 鼻炎药Nasonex和哮喘药Dulera销售保持相对稳定[168,169] - 关节炎药Arcoxia和皮质激素Diprospan销售分别保持稳定和大幅增长[171,172] 税务和财务情况 - 有效所得税率分别为16.0%和14.4%[188] - 2024年1月1日起,大多数欧盟成员国实施了OECD的15%全球最低企业税率[189] - 截至2024年6月30日,公司现金及现金等价物为7.04亿美元[190] - 公司通过经营活动产生的现金流增加,主要是由于应收账款回款时间的影响[193] - 公司将继续分离供应链,从默克公司分离,以优化制造和供应网络[196] - 公司将在2024年支付更高的现金税款[197] - 公司已批准进一步优化制造和供应网络的计划,预计将产生相关成本[196] 风险管理 - 公司面临外汇风险,主要涉及欧元、瑞士法郎和日元[201] - 公司长期债务组合包括固定利率和浮动利率工具,浮动利率债务将受到利率变动的影响[202] - 公司已建立资产负债表风险管理计划和净投资套期,以减轻外汇波动的影响[201]

Organon (OGN) reported $1.61 billion in revenue for the quarter ended June 2024, representing a year-overyear decline of 0.1%. EPS of $1.12 for the same period compares to $1.31 a year ago. The reported revenue represents a surprise of -1.13% over the Zacks Consensus Estimate of $1.63 billion. With the consensus EPS estimate being $1.06, the EPS surprise was +5.66%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...